CNST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CNST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Constellation Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $3.37 Mil. Constellation Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $0.00 Mil. Constellation Pharmaceuticals's annualized EBITDA for the quarter that ended in Mar. 2021 was $-159.48 Mil. Constellation Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2021 was -0.02.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Constellation Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
During the past 5 years, the highest Debt-to-EBITDA Ratio of Constellation Pharmaceuticals was -0.02. The lowest was -0.50. And the median was -0.22.
The historical data trend for Constellation Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Constellation Pharmaceuticals Annual Data | |||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||
Debt-to-EBITDA | -0.32 | -0.12 | - | -0.50 | -0.03 |
Constellation Pharmaceuticals Quarterly Data | ||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.41 | -0.35 | -0.30 | -0.03 | -0.02 |
For the Biotechnology subindustry, Constellation Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Constellation Pharmaceuticals's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Constellation Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (3.644 | + | 0.582) | / | -122.812 | |
= | -0.03 |
Constellation Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2021 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (3.365 | + | 0) | / | -159.48 | |
= | -0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2021) EBITDA data.
Constellation Pharmaceuticals (NAS:CNST) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Constellation Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Emma Reeve | officer: Chief Financial Officer | C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451 |
Column Group L P | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Karen Valentine | officer: See Remarks | C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421 |
Mark A Goldsmith | director, 10 percent owner | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Jeffrey Humphrey | officer: Chief Medical Officer | C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
Steven L. Hoerter | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Elizabeth Trehu | director | C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138 |
Scott Braunstein | director | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
James E Audia | director | 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142 |
Adrian Senderowicz | officer: Chief Medical Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Jigar Raythatha | director, officer: See Remarks | C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Patrick Trojer | officer: Chief Scientific Officer | 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142 |
Richard S Levy | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Ponoi Management, Llc | 10 percent owner, other: General Partner | 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
David V Goeddel | 10 percent owner, other: Managing Partner | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
From GuruFocus
By Marketwired Marketwired • 12-06-2020
By Marketwired Marketwired • 01-07-2021
By Marketwired Marketwired • 06-02-2021
By Marketwired Marketwired • 06-04-2021
By Marketwired Marketwired • 06-11-2021
By PRNewswire PRNewswire • 06-05-2021
By Marketwired Marketwired • 10-19-2020
By PRNewswire PRNewswire • 06-02-2021
By Marketwired Marketwired • 02-18-2021
By PRNewswire PRNewswire • 06-08-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.